Varenykh G.V.

Varenykh G.V.

Auto-generated profile, based on publicly available information

Varenykh G.V.

Belgorod State National Research University, Belgorod, Russian Federation

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2021 in "Medical & Pharmaceutical Journal "Pulse"
Verified
Journal Article
Closed access
ULUstinova L.P.
Ustinova L.P.
IFIrina Filina
Irina Filina
VGVarenyk G.V.
Varenyk G.V.
MEMaltsev E.A.
Maltsev E.A.
Drug therapy is one of the main components of medical care for the population, and the provision of drugs is an important indicator of its availability and quality. The purpose of our work was to analyze satisfaction with the quality of the provision of services for preferential drug provision. The works of domestic and foreign scientists in the field of preferential drug provision, as well as regulatory and organizational documentation on pharmaceutical activities were taken as an information base. The survey method served as the main research method. The objects of the study were the visitors of the pharmacy organizations of the Oryol region, who receive drugs under the program of preferential drug provision. The study found that 49.0% of respondents had difficulties in making an appointment with a doctor; cases of refusal to issue a prescription were indicated by 29.0% of the respondents; 45.0% of the respondents had to spend a long time on obtaining a preferential prescription for a drug by the decision of a medical commission. The majority of respondents (54.0%) do not receive medicines on preferential terms on time (postponed for more than 10 days). Almost half of the surveyed respondents (48.0%) are not satisfied with the treatment with prescription drugs prescribed under the program of preferential drug provision, due to the lack of drugs prescribed by a doctor in the pharmacy organization at the time of contact and their preference for drugs from other manufacturers. Most of the respondents (61.0%) consider the range of preferential drugs to be insufficient for the treatment of their underlying disease. Some respondents (20.0%) are not satisfied with the service in a pharmacy organization; 19.0% are dissatisfied with the quality and completeness of information about medicines received from a doctor and a pharmacy worker. The results obtained were communicated to the management of medical and pharmaceutical organizations serving privileged categories of citizens in the Oryol region. The authors of the study developed a Standard Operating Procedure “Procedure for Selling Medicines to Beneficial Categories of Citizens”, which helps to optimize the quality of service in pharmacies for the population receiving medicines under the preferential drug provision program.

29 February 2024 in "Medical & Pharmaceutical Journal "Pulse"
Verified
Journal Article
Closed access
BYButsykina Y.O.
Butsykina Y.O.
SISpichak I.V.
Spichak I.V.
VGVarenykh G.V.
Varenykh G.V.
ZIZhirova I.V.
Zhirova I.V.
The Russian pharmaceutical market (RPhM) has a large assortment portfolio of medicines (MP) used to treat various diseases of the digestive system. But not all of these drugs are approved for use in children and adolescents. Due to their insufficient safety for this age group, it is necessary to be more careful in the selection of suitable medicines that will not be inferior in effectiveness to other drugs used in adults. So, in particular, some medicines used for the treatment of digestive organs are included in the List of vital and essential medicines, according to the decree of the Government of the Russian Federation dated 12.10.2019 No. 2406-r "On approval of the List of VED for 2023, as well as lists of medicines for medical use and the minimum range of medicines necessary for the provision of medical care." The purpose of this study was to analyze the range of drugs on the Russian pharmaceutical market used for the treatment of gastroduodenitis in adolescents. In the course of the study, various official information sources about medicines registered in the territory of the Russian Federation were reviewed and studied: the Register of Medicines of Russia "RADAR" (2023), Internet sources, collections and forms containing statistical data. Research methods: content analysis, ranking, graphic, structural, segmentation, comparative. A marketing study of the product portfolio was conducted, its structure was formed, and a macro-contour of RPhM drugs used for the treatment of gastroduodenitis in adolescents was developed. Research methods: content analysis, ranking, graphic, structural, segmentation, comparative. A marketing study of the product portfolio was conducted, its structure was formed, and a macro-contour of RPhM drugs used for the treatment of gastroduodenitis in adolescents was developed.

30 March 2024 in "Medical & Pharmaceutical Journal "Pulse"
Verified
Journal Article
Closed access
PEPafenrot E.A.
Pafenrot E.A.
SISpichak I.V.
Spichak I.V.
VGVarenykh G.V.
Varenykh G.V.
ZIZhirova I.V.
Zhirova I.V.
KEKovaleva E.V.
Kovaleva E.V.

29 June 2025 in "Medical & Pharmaceutical Journal "Pulse"
Verified
Journal Article
Closed access
NRNikitin R.O.
Nikitin R.O.
IFIrina Filina
Irina Filina
VGVarenykh G.V.
Varenykh G.V.
Type 2 diabetes mellitus (T2DM) is one of the most prevalent chronic conditions, requiring continuous monitoring and pharmacological support. However, the level of awareness among pharmacy staff regarding T2DM and their readiness to provide counseling may vary significantly. The aim of the study was to assess the knowledge and informational needs of pharmacists in the Belgorod region concerning the counseling of T2DM patients, as well as to analyze the needs of diabetic patients. The study involved 155 pharmaceutical specialists from the Belgorod region. The analysis revealed that 54.2% of respondents considered their knowledge of T2DM to be comprehensive, 31.6% rated it as superficial, and 14.2% as unsatisfactory. Assessment of factual knowledge showed that only 72.2% correctly identified the primary symptoms of T2DM, while 61.9% recognized its complications. At the same time, a quarter of respondents reported difficulties in counseling diabetic patients. The main sources of information for pharmacy staff were webinars (65.8%) and medical reference materials (58.7%). The overwhelming majority of professionals (92.3%) expressed a need for additional training. In the patient-focused segment of the study, 396 individuals participated. Satisfaction with medical care was relatively high: 77.8% of patients were content with their physician consultations, and 72.2% positively evaluated the clarity and completeness of prescribed treatment information. However, 55.6% of respondents believed that pharmacy staff lacked sufficient competence in counseling on medication selection, usage, and dispensing. The demand for pharmaceutical information among patients was exceptionally high: 94.4% wanted details about drug synonyms and alternatives, 66.7% were interested in drug interactions, 55.6% sought information on diabetes prevention and risk reduction strategies, and half of the patients desired guidance on indications, administration rules, and medication costs. 50% of respondents preferred domestically produced medications, while 61.1% felt that the current pharmaceutical market offerings were insufficient for effective diabetes management. Additionally, 61.1% reported having to purchase diabetes medications and supplies at their own expense. The findings of this study can be utilized to enhance continuing education programs for pharmacists, optimize counseling services for diabetic patients, and improve the overall quality of pharmaceutical care for individuals with diabetes.

30 December 2022 in "Medical & Pharmaceutical Journal "Pulse"
Verified
Journal Article
Closed access
VGVarenykh G.V.
Varenykh G.V.
SYSangalova Yu.E.
Sangalova Yu.E.
NRNikitin R.O.
Nikitin R.O.
ZIZhirova I.V.
Zhirova I.V.
Drugs and feed additives based on milk protein in the pharmaceutical veterinary market are a topical trend today. This is due to the relative cheapness of the raw material base, as well as the abundance of dairy farms in Russia. This feature allows to obtain the necessary preparations for all types of animals, not depending on the export of raw materials. Feed additives and pharmaceuticals based on milk protein have a wide pharmacological spectrum of action, which is also an advantage in the development of new drugs and their combinations, dosage forms, as well as updating the existing base of pharmaceuticals in Russia. The aim of the study was to analyze the Russian pharmaceutical market of drugs and feed additives based on milk protein used in veterinary practice. The study examined the information array of official sources of information of feed additives and veterinary medicines registered in the Russian Federation: State Register of Veterinary Drugs (2021); State Register of Veterinary Feed Additives (2021); Encyclopedia of Veterinary Drugs. Register of Veterinary Medicines (2021); Drugs in Russia (2020); Internet resources. Research methods: content analysis, structural, graphical, segmentation analysis, ranking and grouping. A marketing analysis of the Russian pharmaceutical market of veterinary drugs based on milk protein was conducted. The structure of the assortment of veterinary drugs represented in the Russian pharmaceutical market was formed. The macro-outline of the Russian pharmaceutical market of modern feed additives containing milk protein was developed.

30 November 2022 in "Medical & Pharmaceutical Journal "Pulse"
Verified
Journal Article
Closed access
NRNikitin R.O.
Nikitin R.O.
IFIrina Filina
Irina Filina
VGVarenykh G.V.
Varenykh G.V.
SYSangalova Yu.E.
Sangalova Yu.E.
LOLositskaya O.S.
Lositskaya O.S.
Content analysis of statistical data for the Russian Federation and the Belgorod region showed a trend of increasing prevalence of type 2 diabetes mellitus. Currently, according to the State Register of Patients with Diabetes Mellitus and the Federal State Statistics Service, as of January 1, 2022, more than 4.5 million patients were registered in Russia, which is slightly more than 3.1% of the country's population. In the Belgorod region on 01.01.2021, the number of patients with type 2 diabetes was 57,634 people or 3.74% of the population of the region. The increase in the dynamics of the prevalence of diabetes mellitus, its complications, disability and mortality determine the expediency of studying the range of lipid-lowering drugs to improve medical and pharmaceutical care for diabetic patients. The purpose of the study was a marketing analysis of the pharmaceutical market of medicines for the treatment of type 2 diabetes mellitus. Information and reference literature on the range of medicines registered and approved for use in the Russian Federation, Internet resources, supplier offers, scientific works of Russian and foreign scientists were used as objects of research. The study and analysis of the assortment were carried out using a wide range of methods and approaches to research, including generalization and data mining, general scientific analysis tools, statistical methods. In the course of the study of the range of lipid-lowering drugs in the domestic and local markets, the multidimensional characteristics of these segments were obtained. Based on the maximum indicators of the assortment, macro- and mesocontures of target segments of the markets of medicines for the treatment of type II diabetes mellitus have been developed: domestic and Belgorod markets of drugs for the treatment of type II diabetes mellitus The types are represented by: mostly subgroup A10BA - "Biguanides", according to the active substance "Metformin". In terms of composition, drugs with one active ingredient in solid dosage form in the form of tablets are leading. The coefficient of assortment renewal in the Russian pharmaceutical market was 0.75, in Belgorod – 0.51. In general, the study showed that the pharmaceutical market of the Russian Federation has a significant resource for pharmacotherapy of type 2 diabetes mellitus, which provides an opportunity for interaction between pharmaceutical specialists and healthcare professionals to provide pharmaceutical and medical care.